Infusion Associates offers one IV medication and two active research studies to aid in the treatment and prevention of COVID-19. There is no cost to become involved in our research studies (and you are compensated for your involvement), and there are options for both low-risk healthy individuals as well as higher risk immunocompromised individuals.
According to the CDC, COVID-19 is a respiratory disease caused by SARS-CoV-2, a new coronavirus discovered in 2019. The virus is thought to spread mainly from person to person through respiratory droplets produced when an infected person coughs, sneezes, or talks. Some people who are infected may not have symptoms. For people who have symptoms, illness can range from mild to severe. Adults 65 years and older and people of any age with underlying medical conditions are at higher risk for severe illness. People 6 months of age and older should get COVID-19 vaccines to prevent getting and spreading the illness.
We are only able to administer this medication at our Grand Rapids, MI location. Please speak with your healthcare provider for more information if you think this therapy might be right for you.
VEKLURY® is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) who are:
• Hospitalized, or
• Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.
Clinical Research Studies
AstraZeneca Study for the Prevention of COVID-19
The SUPERNOVA Study is looking for people with an impaired immune system to take part. This study is looking at an investigational medication called AZD3152 (study drug) that is designed to protect people with an impaired immune system from contracting COVID-19.
You, or someone you care for, may be able to take part if you/they:
- Are 12 years of age or older
- Have an impaired immune system
- Have not tested positive for COVID-19 or received a COVID-19 vaccine in the past 3 months
- Weigh at least 40 kg
People whose immune system is impaired from a disease, treatment, or a difference in their genes often need additional help to fight infections. This study will look at the study drug to see if it is safe in people with an impaired immune system.
For more information about this study, download the study flyer.
NIH Study for COVID-19 (IV Medication)
The study team hopes to find out if giving anti-SARS-CoV-2 hyperimmunoglobulin (hIVIG) to people early in their infection with COVID-19, before the body has had a chance to make its own antibodies, can help prevent bad effects from COVID-19 and enable them to stay out of the hospital.
You may be able to join the study if you:
- Are 55 or older, OR are 18 or older with a weakened immune system
- Have tested positive for COVID-19 within the past 5 days
- Are not having symptoms, OR have had symptoms for 5 days or less
- Are not currently hospitalized
If you join this study, you will be compensated for your time and travel, and receive either study drug (hIVIG) or placebo given through a vein in the arm as a single dose. You will also get the usual treatment and care for COVID-19 according to local guidelines. The study lasts 28 days with some of the scheduled study visits taking place over the phone.
Frequently Asked Questions
- Ask your healthcare provider to fax us a completed order form for your medication, clinical notes, demographics and your insurance card to (616) 818-4484.
- Providers can find order forms on our medications page.
- We will then verify benefits, obtain any required prior authorizations, and contact you to schedule an appointment.